AVE 5688
Latest Information Update: 04 Oct 2005
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Glycogen phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 31 Mar 2005 Discontinued - Phase-I/II for Diabetes mellitus in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 15 Apr 2004 Phase-I/II clinical trials in Diabetes mellitus in France (unspecified route)